Abstract Guillain-Barré syndrome (GBS) is an acute polyradiculoneuropathy with a highly variable clinical presentation, course, and outcome. The factors that determine the clinical variation of GBS are poorly understood which complicates the care and treatment of individual patients. The protocol of the ongoing International GBS Outcome Study (IGOS), a prospective, observational, multicenter cohort study that aims to identify the clinical and biological determinants and predictors of disease onset, subtype, course and outcome of GBS is presented here. Patients fulfilling the diagnostic criteria for GBS, regardless of age, disease severity, variant forms, or treatment, can participate if included within 2 weeks after onset of weakness. Information about demography, preceding infections, clinical features, diagnostic findings, treatment, course, and outcome is collected. In addition, cerebrospinal fluid and serial blood samples for serum and DNA is collected at standard time points. The original aim was to include at least 1,000 patients with a follow-up of 1-3 years. Data are collected via a web-based data entry system and stored anonymously. IGOS started in May 2012 and by January 2017 included more than 1,400 participants from 143 active centers in 19 countries across 5 continents. The IGOS data/biobank is available for research projects conducted by expertise groups focusing on specific topics including epidemiology, diagnostic criteria, clinimetrics, electrophysiology, antecedent events, antibodies, genetics, prognostic modeling, treatment effects, and long-term outcome of GBS. The IGOS will help to standardize the international collection of data and biosamples for future research of GBS.
Introduction
Guillain-Barré syndrome (GBS) is an acute polyradiculoneuropathy clinically characterized by a rapidly progressive symmetrical flaccid weakness of the limbs (van den Berg et al., 2014; Willison et al., 2016) . The clinical presentation, course, and outcome of GBS are variable. Some patients have mild weakness of the lower legs only, while others develop complete tetraplegia and respiratory failure requiring mechanical ventilation (van den Berg et al., 2014; Willison et al., 2016) . Patients may have variant forms of GBS, including Miller Fisher syndrome (MFS), pure motor, paraparetic, or pharyngeal-cervical-brachial forms (van den Berg et al., 2014; Wakerley et al., 2014; Willison et al., 2016) . The electrophysiological findings are equally heterogeneous with subgroups of patients showing features of either demyelination or axonal degeneration (Ho et al., 1995; Hadden et al., 1998; Uncini and Kuwabara, 2012) . The clinical recovery also varies: some patients recover spontaneously with no residual limitations, while others require mechanical ventilation for months and remain wheel chair bound for the rest of their lives or even die despite treatment (van den Berg et al., 2014; Willison et al., 2016) . Independent of the GBS subtype, severity, or predicted outcome, the standard treatment regimen for the past two decades has consisted of intravenous immunoglobulin (IVIg) or plasma exchange (Hughes et al., , 2014 Raphael et al., 2012) . Despite treatment, outcome of GBS is frequently poor because 2%-5% of the patients die and 10%-20% of patients remain severely disabled Fokke et al., 2014; Willison et al., 2016) . Outcome is even worse in low-income countries: in Bangladesh, for example, 85% of patients receive no treatment, 15% die, and 30% remain severely disabled (Islam et al., 2010) . These findings show the need for more effective, personalized, and accessible treatments worldwide.
The factors that determine the heterogeneity of GBS and that could provide a basis to personalize treatment are largely unknown. Previous studies observed an association between the clinical course in patients and the acute phase clinical characteristics or biomarkers such as electrophysiological subtype, preceding infections, anti-ganglioside antibodies, serum levels of IgG, and albumin and genetic polymorphisms (Geleijns et al., 2006; van Koningsveld et al., 2007; Kusunoki et al., 2008; Kuitwaard et al., 2009; Walgaard et al., 2010 Walgaard et al., , 2011 Walgaard et al., , 2017 Fokkink et al., 2017) . However, most of these studies were retrospective, and the findings were derived from relatively small series or selected groups of patients with a short follow-up period using a limited set of suboptimal outcome measures. In addition, the variety in inclusion criteria and methods used in these studies complicates comparing or combining collected data. Moreover, GBS varies considerably between geographical regions (Mori et al., 2012; Kuwabara and Yuki, 2013; Willison et al., 2016) . Solving these problems requires a prospective study design with standardized collection of clinical data and biomaterials from a large group of well-defined GBS patients with a long follow-up period. The International GBS Outcome Study (IGOS) was initiated to collect the required clinical data and biosamples. After several organizational meetings, a final study protocol was prepared, and local investigators were invited to participate. IGOS is being conducted in collaboration with the Peripheral Nerve Society and Inflammatory Neuropathy Consortium (INC) (www.pnsociety.com/inflammatory-neuropathyconsortium/), an international organization of clinical neurologists and scientists involved in the investigation and care of patients with GBS.
Study aim and objectives
The overall aim of IGOS is to determine the clinical and biological determinants and predictors of the clinical course and outcome of GBS. The objectives are: (1) to define the variation in clinical presentation, subtypes, progression, and recovery of GBS in patients from a broad range of geographical areas, (2) to describe the current practice of diagnosis, treatment, and care for GBS, (3) to identify environmental and host factors that determine the disease onset and the variation in clinical course, treatment response, and outcome, (4) to develop improved prognostic models to predict the clinical course and outcome in individual patients, and (5) to facilitate the collection of standardized and relevant data and biosamples for future studies of GBS.
Methods and Materials

Study design
IGOS is an international, prospective, observational, multicenter cohort study. It uses a pre-defined protocol to collect data regarding baseline characteristics, clinical presentation and course, electrophysiology, diagnosis, treatment, and outcome during a follow-up of 1 year with the possibility to extend the follow-up to 2 or 3 years (Fig. 1) . The protocol specifies the timing of the collection of biosamples, including blood for DNA and serum studies and cerebrospinal fluid (CSF). Predictive models for the clinical course and outcome will be based on results collected in the first 2 weeks. The first 1,000 participants will constitute a derivation cohort. The next 500 or more patients will provide a validation cohort. The filled blocks refer to obligatory studies, the striped to optional substudies. The timeline represents the follow-up period after study entry in weeks. The first 2 weeks focus on collecting data and biomaterials to predict the clinical course and outcome in the period after 2 weeks. Blood samples are obtained as indicated for serial serological studies and for DNA extraction. Routine diagnostic electrophysiology will be conducted in the first or second week, and as an optional study at 4 weeks. *At 8 weeks and 13 weeks patients admitted at the hospital will have a full examination and serum sampling but discharged patients will have telephone assessment only and no serum sampling.
1 Patient reported outcome measures (PROM) used are Rasch-built Overall Disability Score (R-ODS), Fatigue Severity Scale (FSS), Rasch-FSS, EuroQol EQ-5D.
Inclusion and exclusion criteria for patients
Inclusion requires fulfilling the following criteria:
1 The diagnostic criteria for GBS of the National Institute of Neurological Disorders and Stroke (NINDS) (See Table S1 , Supporting Information), or one of the variants of GBS, including the MFS and overlap syndromes (Asbury and Cornblath, 1990; Sejvar et al., 2011; Wakerley et al., 2014) . 2 Entry within 2 weeks of onset of weakness (or other symptoms attributed to GBS). 3 Opportunity to continue a follow-up for at least 1 year. 4 Informed consent of the participant or, for children, the parents or legal guardians.
The aim is to enroll patients representing the full spectrum of GBS. There are no exclusion criteria, and all patients with GBS or its variants, including MFS and overlap forms, may participate, regardless of age, disease severity, or treatment.
IGOS data-and biobank
Baseline, clinical, and treatment data
We collect baseline data about the patients' demography, comorbidity, family history, and antecedent events. In addition, we record the first clinical symptoms and signs of GBS, the timing and key features of the diagnosis, hospital transfers, neurological examination findings and the clinical course.
The severity and distribution of clinical manifestations of GBS will be documented in detail, including cranial nerve deficits, limb weakness using the Medical Research Council (MRC) sum score (Kleyweg et al., 1991) and Rasch-built MRC score (Vanhoutte et al., 2012) , sensory deficits, ataxia, limb tendon reflexes, GBS disability scale (Hughes et al., 1978) , pain, autonomic dysfunction, respiratory failure, and associated medical complications. In addition, we record the occurrence of treatment-related fluctuations and transitions to chronic inflammatory demyelinating polyneuropathy . From 4 weeks onward, we collect the following clinical outcome measures: Overall Neuropathy Limitation Scale (ONLS) (Graham and Hughes, 2006) , Rasch-built Overall Disability Score (R-ODS) (van Nes et al., 2011) , Fatigue Severity Scale (FSS) (and Rasch-built FSS) (van Nes et al., 2009 ) and the EuroQol EQ-5D health questionnaire (Brooks, 1996) (Fig. 1) . A complete neurological examination will be performed at study entry and after 1, 2, 4, 26 (±2), and 52 (±4) weeks. Participants still in hospital at 8 (±1) and 13 (±1) weeks will be examined but those who have been discharged have only a telephone assessment of the GBS disability scale, ONLS, R-ODS, FSS, and EuroQoL EQ-5D. All patients reported outcome measures have been translated (and back translated) into the language of the participants. We collect detailed information about the treatment for GBS including the type, timing, regimen and side effects of treatment, admission to intensive care, and start and end of mechanical ventilation. If a patient dies, we document the timing and cause of death.
Electrophysiology data
We collect the results of the routine diagnostic electrophysiological examinations, including the raw data and the local investigators' interpretation and classification of the subtype, including acute inflammatory demyelinating polyneuropathy, acute motor axonal neuropathy, acute motor-sensory axonal neuropathy, inexcitable nerves, and equivocal or normal results. The study protocol recommends performing electrophysiological studies according to a pre-defined standard format (Table S2 ). Some clinics routinely perform a second diagnostic nerve conduction study and we collect these results when available. We document locally used normative values and standard electrophysiology protocols.
Blood samples
We collect blood and CSF samples according to a pre-defined schedule (Fig. 1) . Blood samples provide serum and DNA. The protocol specifies that the first serum sample is to be collected before the start of treatment, although in some patients treatment is being initiated before study entry (e.g., when patients transfer to a center participating in IGOS after treatment at a local community hospital). Blood samples are frozen and stored at −80 ∘ C (or initially stored −20 ∘ C for a maximum of 6 months) at the local center or at the center of the country coordinator, and transported on dry ice to a central biobank, at Erasmus MC in Rotterdam, the Netherlands, with a reserve biobank at the University of Glasgow, Scotland, UK.
Cerebrospinal fluid samples
If participants have a routine lumbar puncture to examine CSF for diagnostic studies, we keep an aliquot for biomarker studies. In centers participating in an advanced proteomics study, an extra aliquot is sampled (Teunissen et al., 2009) . This study requires centrifugation of the CSF sample within 1 h after the lumbar puncture. The supernatant (without pellet) is removed and immediately stored in a polystyrene tube at −20 ∘ C until being transferred to the country coordinating center and stored at −80 ∘ C. This optional research module requires additional informed consent.
Extended follow-up of 2 and 3 years
The time course of nerve regeneration and clinical recovery in GBS is unclear. Some patients continue to improve even after 1 year (Dhar et al., 2008; Rudolph et al., 2008) . To determine the further recovery and long-term residual deficits, there is an optional long-term follow-up research module with a telephone assessment at 2 years (104 ± 4 weeks) and 3 years (156 ± 4 weeks) after onset. The data collected then include the GBS disability score, ONLS, R-ODS, FSS (and Rasch-FSS), and EuroQoL EQ-5D. Severely affected patients may have more extensive evaluation including neurological examination at each visit. The long-term follow-up requires additional informed consent.
Children with GBS
Children with GBS differ from adult patients regarding their preceding infections, clinical features, GBS subtype, treatment, and outcome (Korinthenberg et al., 2007; Roodbol et al., 2011) . In children, it is more difficult to obtain biosamples and the adult outcome measures have not all been validated. For this reason, we are using an adapted protocol for children with age-dependent sampling of biomaterials and clinical assessment scales.
Data collection
We have developed a web-based data entry system that meets the standards of security and privacy of Erasmus MC, the host institution. The local investigators use this website to enter the data. The information stored is strictly anonymous. All participants have a unique code for use throughout the study. The quality of the collected data is controlled regularly by the IGOS Coordinating Center according to protocol and additional controls will be conducted by the IGOS Expertise Groups.
Sample size
The extent of the clinical variation of GBS in the world is currently unknown and limits the possibility to conduct a power calculation. There is only circumstantial evidence available to estimate the required size of the study. It is recommended for the development of predictive logistic regression models that the smallest outcome group should include at least 100 patients (Vergouwe et al., 2005) . Previous therapeutic trials with GBS-defined poor outcome as a GBS disability score of >2 (not being able to walk unaided or worse) (Hughes et al., 1978) . In treatment trials, about 10%-15% of participants have had a poor outcome after 1 year van Koningsveld et al., 2007) . If we aim to include at least 100 participants with a poor outcome defined in this way, the whole study will need at least 1,000 participants. Therefore, this is the minimum size of the derivation cohort to identify new clinical and biological markers to predict poor outcome or evaluate previously described prognostic factors. In addition, we collect an independent validation cohort of at least 500 patients to validate any new clinical or biomarkers that emerge from the derivation cohort.
Statistical analyses
Descriptive statistics are used to analyze the clinical data. We will develop prognostic models to evaluate the use of biomarkers and clinical characteristics to predict outcome in clinical practice according to our previously published statistical approaches Walgaard et al., 2010 Walgaard et al., , 2011 . The association between putative prognostic factors and outcome variables will be analyzed using univariate and multivariable logistic regression models. If two similar variables are equally associated with outcome, the variable most easily obtainable in clinical practice will be selected. We will quantify model performance with respect to discrimination (area under receiver operating characteristic curve). Multivariable regression coefficients will be used to develop new prognostic models for GBS.
IGOS consortium and IGOS research policy agreement
IGOS is conducted by the IGOS Consortium which consists of (1) the members of the Steering Committee, (2) the staff of the Coordinating Center at Erasmus MC, Rotterdam, the Netherlands, (3) the Country Coordinators, and (4) their networks of local investigators (see Appendix). To be able to participate in IGOS and to become a member of the IGOS Consortium all participants signed the IGOS Consortium Agreement, which defined the conduct of the study. All members of the IGOS Consortium can apply to the Steering Committee to use the IGOS data/biobank to address specific research questions. Research projects are also being conducted by the Expertise Groups, consisting of members of the IGOS Consortium and additional researchers if external expertise is required.
Ethical regulations
The IGOS received approval from the Medical Ethics Review Committee of the Erasmus MC Medical University Rotterdam in 2012. Each participating center also had approval from their local Institutional Review Board (IRB). The IGOS is being conducted according to the principles of the Declaration of Helsinki (59th WMA General Assembly, Seoul, October 2008) and the Medical Research Involving Human Subjects (WMO). The procedures set out in this protocol were designed to ensure that the investigators abide by the principles of the GCP guidelines of the European Community (ICH topic E6, CPMP/ICH/135/95, Directive 2001/20/EC) in the conduct, evaluation and documentation of this study. Inclusion in IGOS requires informed consent from each participant or their legal representative. IGOS was registered before the start of the study at ClinicalTrials.gov identifier (NCT01582763).
Discussion
IGOS started in May 2012 and in June 2015 IGOS had enrolled 1,000 patients who will form the derivation cohort (Fig. 2) . By January 2017, more than 1,400 patients with GBS had been included in IGOS by 143 active sites from 19 countries across 5 continents (Fig. 3) . We are continuing to recruit more patients to complete the independent validation cohort, and anticipate enrollment of 1,500 patients by July 2017.
IGOS has important advantages over previous observational studies of GBS. First, IGOS already includes the largest number of prospectively collected patients with a confirmed diagnosis of GBS. Second, there was no selection of patients based on age, clinical subtype, or severity, aiming to investigate the full range of variants within the spectrum of GBS. Third, we collected data from patients from various geographical regions, including high-and low-income countries using the same protocol and will be able to compare and contrast various attributes of the condition worldwide. Fourth, IGOS has a long follow-up period and uses several well-defined and validated outcome measures to assess the long-term outcome of GBS. Fifth, we are collecting biosamples prospectively according to the protocol at recruitment and follow-up visits coinciding with clinical assessments. We will use these samples to study preceding infections, antibodies to peripheral nerves and other immunological factors, pharmacokinetics, genetic factors, and other potential biomarkers for correlation with clinical features. Because of these advantages, IGOS will provide the most extensive research data-and biobank of GBS patients collected so far. This will enhance our understanding of the pathogenesis and the individual clinical course, prognosis, treatment response, and outcome. The overall aim is to develop more effective personalized treatment regimens based on a better understanding of the variation of the disease (Fig. 4) .
IGOS has already enhanced international collaboration in research into the cause and treatment of GBS by strengthening international networks. Expertise Groups will be formed on various topics including (1) emerging preceding events related to GBS, (2) diagnostic criteria and protocols for GBS, (3) electrophysiological subtypes of GBS, (4) biological determinants including genetic polymorphisms, preceding infections, and serum antibodies in the pathogenesis of GBS and its subtype, (5) biomarkers for monitoring treatment, pharmacokinetics, and disease activity, (6) validating and improving outcome measures, (7) long-term outcome, (8) prediction of prognosis, and (9) improving treatment.
By providing an infrastructure for standardized collection of data and biomaterials, IGOS will facilitate international research projects on emerging infections associated with GBS, such as the recent outbreak of Zika virus infection (Cao-Lormeau et al., 2016; Parra et al., 2016) . This infrastructure will also help to record other emerging preceding events that have been previously related to the development of GBS, including vaccinations. Our aim is also to use the international expertise involved in IGOS and the collected materials to compare and standardize assays for relevant biomarkers in GBS including preceding infections, antibodies, genetic polymorphisms, and pharmacokinetic analysis. The extensive recording of the clinical course and outcome at serial visits during long-term follow-up provides a unique opportunity for international validation of outcome measures that so far have been developed in limited regions only. The IGOS data-and biobank provide an easily accessed source of control natural history data for modeling studies and comparison with patients treated with novel treatment regimens. One ongoing study is already comparing one with two courses of IVIg in patients with a poor 
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